Post-Meeting Materials

• Plenary Session Presentations
• Pandemic Influenza Breakout Session Presentations
• Biological Threats Breakout Session Presentations
• Radiological/Nuclear Threats Breakout Session Presentations
• Chemical Threats Breakout Session Presentations
• Executive Summary
• Participant List

Plenary Session Presentations

• Animal Models for Assessing Countermeasures to Bioterrorism Agents
  Linda Anestidou, D.V.M., Ph.D.

• EU: Regulatory Procedures for the Authorisation of Vaccines Against Influenza A (H1N1)
  Sabine Atzor

• Strategic National Stockpile: Overview
  Coordinating Office for Terrorism Preparedness and Emergency Response, CDC

• Liability Protection for Public Health Countermeasures
  John M. Clerici

• Canadian MedCM Consortium
  R.K. Harding

• Emergency Use of Medical Countermeasures
  Cynthia L. Kelley, M.S.

• Medical Countermeasures Programs on BioDefense, Radiological/Nuclear and Chemical Threats at the National Institute of Allergy and Infectious Diseases
  Michael G. Kurilla, M.D., Ph.D.

• The Global Health Security Initiative (GHSI) Public Health Emergency Medical Countermeasures (MCM) Workshop
  Nigel Lightfoot, C.B.E.
  

• The U.S. Public Health Medical Countermeasure Enterprise
  Carol D. Linden, Ph.D.

• WHO Coordination Efforts to Make Pandemic (H1N1) Vaccines Available Globally
  C. E. Roth

• The WHO Smallpox Vaccine Resource
  C. E. Roth

• The French Medical Countermeasures Program Road Map and Perspectives
  François Salicis

• MCM Markets and Sustainability: The National Biodefense Science Board Approach
  Patrick J. Scannon, M.D., Ph.D.

• Prospects for International Harmonization of the Regulatory Processes for MCM
  Dr. David J. Wood

top of page

Pandemic Influenza Breakout Session Presentations

• Plant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing
  Nathalie Charland, Ph.D.

• Multivalent Vaccine Platform for Pandemic influenza and Biodefense
  Dr. John Y. Dong

• Epidemiology of Infectious Complications of H1N1 Influenza Virus Infection
  Lyn Finelli, Dr.PH, M.S.

• DMID H1N1 Clinical Trials
  Richard L. Gorman, M.D.

• HHS/NIH/NIAID Press Releases about H1N1
  Richard L. Gorman, M.D.

• New Influenza A/H1N1
  René Gottschalk, M.D., Ph.D

• H1N1 Vaccine & Antivirals
  Robin Robinson, Ph.D.

• PREPARED—Preparation & Response to the Emerging Pandemic: Assays, Reagents & Enhanced Distribution
  Mary Hoelscher

• National Pandemic Flu Service: Rapid Antiviral Distribution During H1N1 Pandemic
  Bruce Taylor

• The Japanese H1N1 Vaccination Strategy
  Teppei Kiuchi, M.D., M.P.H.

top of page

Biological Threats Breakout Session Presentations

• NIAID MCM Research and Development at the Health Protection Agency
  Dr. Simon Funnell

• Therapeutic Research within the French RNBC Program
  Daniel Gillet

• Global Health Security Initiative
  Cangene Corporation

• French Anthrax Vaccine Program
  Colonel Françoise Leveque

• U.K. Biodefence Medical Countermeasures Portfolio
  Nigel Lightfoot, C.B.E.

• The Integrated National Biodefense Medical Countermeasures (MCM) Portfolio Initiative
  Carol D. Linden, Ph.D.

• Advanced Development of a Broad Spectrum Antiviral Drug for the Treatment of Smallpox
  George R. Painter, Ph.D.

• Emergent’s Anthrax Programs
  Emergent Biosolutions

• Botulism Diagnostics: Challenges and Requirements
  Susan Maslanka, Ph.D.

• Developing a New Generation of Anthrax Vaccines and Therapeutics
  Dr. Matthew Duchars

• Research and Developments in Smallpox Vaccine LC16m8
  Tomoya Saito, M.D., Ph.D

top of page

Radiological/Nuclear Threats Breakout Session Presentations

• Mitigation of the Hematopoietic Syndrome Resulting From Acute Exposure to Ionizing Radiation: A Therapeutic Solution
  Timothy Gallaher, Ph.D.

• Countermeasures Against Intakes of Radionuclides: Decorporation Research at LRRI
  Raymond A. Guilmette, Ph.D., FHPS, CRadP

• NIH/NIAID Radionuclide Decorporation Agent Development Program
  Nate Hafer, Ph.D.

• BARDA Development and Funding: Chemical, Radiological and Nuclear Portfolio
  HHS/ASPR/BARDA

• Acute and Delayed Effects of ARS: An Animal Model Research Platform to Assess Efficacy of Medical Countermeasures
  Thomas J. MacVittie, Ph.D.

• Radiological Emergency Preparedness in the United Kingdom—Progress in 2009
  Neil McColl

• NIAID/NIH Radiation/Nuclear Medical Countermeasures Development Program
  Narayani Ramakrishnan, Ph.D.

• An Update on WHO Activities on MCM Against Radiation Emergencies
  Zhanat Carr, M.D., Ph.D.

• Treatment of Radiation-Induced Injuries with Mesenchymal Stem Cells: the French Experience
  Jean-Renè Jourdain, Pharm.D., Ph.D.

top of page

Chemical Threats Breakout Session Presentations

• Neurotoxins Countermeasures: the French Military Health Service
  Lieutenant Colonel Bardot Sébastien, Pharma.D.

• HI-6: Oxime Research in Canada, Development of an Intravenous Formulation of HI-6
  Defence Research and Development, Canada

• CounterACT Summary
  Countermeasures Against Chemical Threats

• The Oxime Cost-Effective Stockpile: Lessons Learned from Iran and Japan
  Tetsu Okumura, M.D., Ph.D.

• Overview of MCM Research in Japan
  Tetsu Okumura, M.D., Ph.D.

• Oxime Research in the U.S.A. and Improving Efficacy in the CNS
  Richard K. Gordon, Ph.D.

• Design of Novel Oxime Reactivators and Direct Characterization of Their Interaction With OP-ChE Conjugates
  Zoran Radić, Jaroslaw Kalisiak, Rory Cochran, Limin Zhang, Trevor Dale

top of page

Executive Summary - in Clearance; will be posted shortly.

top of page

Participant List

top of page